These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 26231487)

  • 21. Most patients with HCV-associated lymphoma present with mild liver disease: a call to revise antiviral treatment prioritization.
    Torres HA; Mahale P
    Liver Int; 2015 Jun; 35(6):1661-4. PubMed ID: 25779000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.
    Maylin S; Martinot-Peignoux M; Moucari R; Boyer N; Ripault MP; Cazals-Hatem D; Giuily N; Castelnau C; Cardoso AC; Asselah T; Féray C; Nicolas-Chanoine MH; Bedossa P; Marcellin P
    Gastroenterology; 2008 Sep; 135(3):821-9. PubMed ID: 18593587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.
    Chehadeh W; Al-Nakib W
    J Med Virol; 2009 Apr; 81(4):610-8. PubMed ID: 19235842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A novel FRET probe-based approach for identification, quantification, and characterization of occult HCV infections in patients with cryptogenic liver cirrhosis.
    Bhargava A; Punde R; Varshney S; Pathak N; Mishra PK
    Indian J Pathol Microbiol; 2011; 54(2):420-1. PubMed ID: 21623119
    [No Abstract]   [Full Text] [Related]  

  • 25. Review article: predicting response in hepatitis C virus therapy.
    Mihm U; Herrmann E; Sarrazin C; Zeuzem S
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1043-54. PubMed ID: 16611264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression of hepatic histopathology in kidney transplant recipients with chronic hepatitis C virus infection and effect of immunosuppression on the course of hepatitis C virus infection.
    Korkmaz M; Fakı S; Öcal S; Harmancı Ö; Selçuk H; Haberal M
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():159-64. PubMed ID: 25894147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Hepatitis C Patients in the Direct-Acting Antiviral Era.
    Teriaky A; Reau N
    Clin Liver Dis; 2015 Nov; 19(4):591-604, v. PubMed ID: 26466649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic hepatitis C: from discovery to cure].
    Li Q; Huang YX; Chen L
    Zhonghua Gan Zang Bing Za Zhi; 2016 Sep; 24(9):708-712. PubMed ID: 27788732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Noninvasive methods to assess liver disease in patients with hepatitis B or C.
    Castera L
    Gastroenterology; 2012 May; 142(6):1293-1302.e4. PubMed ID: 22537436
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of fibrosis on response to interferon therapy in Egyptian HCV patients.
    Abdel-Bary EH; Mangoud AM; El-Hady HA; Salama MF; Morsy TA
    J Egypt Soc Parasitol; 2012 Dec; 42(3):665-74. PubMed ID: 23469640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Approaches for treatment of liver fibrosis in chronic hepatitis C.
    Bedossa P; Paradis V
    Clin Liver Dis; 2003 Feb; 7(1):195-210. PubMed ID: 12691467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
    Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular epidemiology of chronic hepatitis C (HCV) virus].
    Nitkiewicz J
    Przegl Epidemiol; 2004; 58(3):413-21. PubMed ID: 15730005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preparing the patient for success: treat or wait?
    Buti M; Esteban R
    Dig Liver Dis; 2013 Sep; 45 Suppl 5():S332-6. PubMed ID: 24091112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Projecting future complications of chronic hepatitis C in the United States.
    Davis GL; Albright JE; Cook SF; Rosenberg DM
    Liver Transpl; 2003 Apr; 9(4):331-8. PubMed ID: 12682882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of HCV genetic differences on pathobiology of disease.
    Ripoli M; Pazienza V
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):747-59. PubMed ID: 21905784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relating the liver damage with hepatitis C virus polymorphism in core region and human variables in HIV-1-coinfected patients.
    Matas M; Picornell A; Cifuentes C; Payeras A; Bassa A; Homar F; López-Labrador FX; Moya A; Ramon MM; Castro JA
    Infect Genet Evol; 2010 Dec; 10(8):1252-61. PubMed ID: 20732459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations.
    Tseng PL; Wang JH; Hung CH; Tung HD; Chen TM; Huang WS; Liu SL; Hu TH; Lee CM; Lu SN
    Kaohsiung J Med Sci; 2013 Jul; 29(7):385-95. PubMed ID: 23768703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epidemiology of viral hepatitis C in the Donetsk region].
    Zaĭtsev IA; Potiĭ VV; Zaplotnaia AA; Demkovich OO
    Lik Sprava; 2014 Nov; (11):122-7. PubMed ID: 25528849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.